News Release

PHILADELPHIA—Minorities and women suffering from a stroke may be less likely to receive the clot-busting treatment tPA, known as tissue plasminogen activator, according to a new study from Penn Medicine and other institutions published today in the online issue of Neurology, the medical journal of the American Academy of Neurology. 

The elderly and those with milder stroke symptoms were also less likely to receive intravenous tPA, the life-saving drug shown to significantly improve chances of cure from stroke disability, after arriving at a hospital.

“The use of intravenous tPA has increased dramatically over the past 10 years, but some eligible patients are still not receiving the treatment. We wanted to understand which factors were associated with failing to treat these patients, so we can improve tPA use in the future,” said first author Steven R. Messé, MD, an associate professor in the division of Vascular Neurology at the Perelman School of Medicine at the University of Pennsylvania. “This data suggests that gender and, to a greater extent, race may play a role in that.”

The researchers conducted a retrospective study of over 61,000 ischemic stroke patients in the United States between 2003 and 2011 who arrived at a hospital within two hours after the start of symptoms and had no documented reasons that they could not receive the treatment. The data was collected from the American Stroke Association’s “Get With The Guidelines–Stroke” (GWTG-Stroke) registry, a national, ongoing, voluntary, registry and quality-improvement initiative that began in 2003 to help improve adherence to clinical guidelines.

Ischemic strokes, a result of an obstruction within a blood vessel supplying blood to the brain, are the more common type, causing over 80 percent of all strokes. It takes the lives of about 140,000 people die every year in the U.S., while almost 800,000 suffer from a stroke every year.

Overall, they found that overall 25 percent of the eligible stroke patients did not receive the treatment. Treatment rates did, however, improve dramatically over time. From 2003 to 2004, 45 percent of eligible patients received treatment compared to 82 percent from 2010 to 2011. 

After adjusting for hospital and patient factors, including stroke severity, women had eight percent greater odds of not receiving treatment than men.  African-Americans had 26 percent greater odds of not receiving treatment than whites, while those of other races had a 17percent greater odds of not receiving treatment than whites. 

The findings are consistent with several prior publications, including data from GWTG-Stroke; however, the current study includes more contemporary treatment data and more extensive adjustment for potential known confounders than many prior studies.  In particular, this study included adjustment for stroke severity, which is one of the most important predictors for short- and long-term outcome, and a very strong predictor for use of tPA.

Additional patient-specific factors associated with non-treatment included history of carotid stenosis, peripheral vascular disease, diabetes mellitus, heart attacks, presence of a prosthetic heart valve, and not presenting to the hospital via EMS. 

The researchers also found, as did previous reports, that people who were treated at hospitals certified as stroke centers were more likely to receive treatment than those at hospitals without the certification, with those at primary stroke centers having nearly twice the odds of receiving tPA. Patients not treated with tPA presented to hospitals that had a smaller number of beds, were less often teaching hospitals or Joint Commission–certified primary stroke centers, and had fewer annual ischemic stroke admissions, the authors found.

The Penn Stroke Center is a Joint Commission-certified Comprehensive Stroke Center, one of only 100 centers in the country.

“To improve use of the clot-busting medication, patients and families should be educated about potential stroke symptoms and encouraged to call EMS if stroke is suspected. Continued development of systems of care for stroke should remain a high priority, as well,” Messé said. “Additional studies should also be taken to address the potential disparities in care for patients with ischemic stroke.”

The study was supported in part by Pfizer, Inc., and the Merck-Schering Plough Partnership.

.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.

Share This Page: